Therapy Areas: Hereditary Disorders
US FDA grants fast track designation to Proteostasis Therapeutics for cystic fibrosis program
6 April 2018 -

The United States Food and Drug Administration (FDA) has granted fast track designation to United States-based Proteostasis Therapeutics for its triple combination program to treat cystic fibrosis, it was reported yesterday.

The firm's proprietary triple combination includes a novel cystic fibrosis transmembrane conductance regulator amplifier, third generation corrector and potentiator, called PTI-428, PTI-801 and PTI-808, respectively.

The company had previously announced that the protocol for its triple combination clinical study, which it plans to initiate in the current quarter, has received endorsement and a high strategic fit score from the Therapeutics Development Network and the Clinical Trial Network, the drug development arms of the Cystic Fibrosis Foundation and the European CF Society, respectively.

The FDA's fast track designation is designed to facilitate the development and accelerate the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical requirements.

Login
Username:

Password:


Related Headlines

Vertex, Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies

Vertex to Submit Cystic Fibrosis Medicines Orkambi as Well as Symkevi to be Used in Combination with ivacaftor, to the Scottish Medicines Consortium for Appraisal

Non–Cystic Fibrosis Bronchiectasis FDA Grants "Fast-Track" and "QIPD" to Zambon for Colistimethate Sodium Powder for Nebulizer Solution Delivered by the I-neb AAD System

Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis

Vertex Receives European CHMP Positive Opinion for Orkambi (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common form of the Disease

Verona Pharma completes patient enrolment for phase two trial of RPL554

Vertex Pharmaceuticals (Europe) receives positive opinion from European watchdog for Kalydeco

Synspira Receives US FDA Orphan Designation for PAAG15A for the Treatment of Cystic Fibrosis

Decibel Therapeutics and Oricula Therapeutics Ink Exclusive License for ORC-13661 in Phase 1 Development for Hearing and Balance Protection

Synedgen Names Parker as Chief Business Officer

Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis, According to Gilead and Galapagos

Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis

Vertex, Genomics Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines

Vertex Receives a Positive PBAC Recommendation for Reimbursement of Orkambi to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation

ELITechGroup Biomedical Systems Launches Macroduct Advanced–A Sweat Induction and Collection Method Cleared by the FDA